| Enthera–SEVERAL: investment, 202007 financing round Series A €28m co-led by Sofinnova Partners + AbbVie Ventures |
2020-07-28 |
| Enthera–Sofinnova: investment, 202007 financing round Series A totalling €28m incl existing + co-lead investor Sofinnova Partners |
2020-07-28 |
| Tubulis–BPCE: investment, 202007 financing round Series A totalling €10.7m incl co-investor Seventure Partners |
2020-07-21 |
| Tubulis–SEVERAL: investment, 202007 financing round Series A €10.7m co-led by BioMedPartners + HTGF |
2020-07-21 |
| Enancio–Illumina: acquisition, 202007 acquisition of Enancio by Illumina |
2020-07-14 |
| Osivax–Trophic Communications: public relations, 202007 service existent by Trophic Communications |
2020-07-08 |
| Sanofi–Kiadis: NK cell therapy, 202007– license ww excl for K-NK004 program + two other programs €17.5m upfront + €857.5m milestones + royalties |
2020-07-08 |
| Citryll–BPCE: investment, 202007 financing round Series A totalling €18.5m incl new + lead investor Seventure incl its Health for Capital II fund |
2020-07-02 |
| Citryll–SEVERAL: investment, 202007 financing round Series A €18.5m led by Seventure + co-led by BioGeneration Ventures |
2020-07-02 |
| Lysogene–Weizmann Institute: gene therapy, 202007– collab research + license option AAV gene therapy for Gaucher + Parkinson diseases |
2020-07-01 |
| Resolution Spectra Systems–Merck (DE): investment, 202007 acquisition €na of Resolution Spectra Systems by Merck |
2020-07-01 |
| Enterome–BPCE: investment, 202006 financing round Series E €na incl existing investor Seventure Health for Life Capital |
2020-06-25 |
| Enterome–Nestlé: investment, 202006 financing round Series E €na incl existing investor Nestlé Health Science |
2020-06-25 |
| Enterome–Omnes Capital: investment, 202006 financing round Series E €na incl existing investor Omnes Capital |
2020-06-25 |
| Enterome–Principia SGR: investment, 202006 financing round Series E €na incl existing investor Principia |
2020-06-25 |
| Enterome–SEVERAL: investment, 202006 financing round Series E €na with existing plus new investors SymBiosis LLC + Takeda Pharma |
2020-06-25 |
| Enterome–SymBiosis LLC: investment, 202006 financing round Series E €na incl new investor SymBiosis LLC |
2020-06-25 |
| Enterome–Takeda: investment, 202006 financing round Series E €na incl new investor Takeda Pharmaceutical Co Ltd |
2020-06-25 |
| RareCyte–Scienion: single-cell dispenser, 202006 supply existent of cellenONE to RareCyte for CTC analysis technology by Cellenion |
2020-06-22 |
| DiogenX–Advent France Biotechnology: investment, 202006 seed financing round totalling €4.5m incl investor Advent France Biotechnology |
2020-06-16 |
| DiogenX–Andrew Lloyd Associates: public relations, 202006 service existent by ALA |
2020-06-16 |
| DiogenX–Boehringer: investment, 202006 seed financing round totalling €4.5m incl investor BIVF |
2020-06-16 |
| DiogenX–Juvenile Diabetes Research Foundation: investment, 202006 seed financing round totalling €4.5m incl investor JDRF T1D Fund |
2020-06-16 |
| DiogenX–SEVERAL: investment, 202006 seed financing round €4.5m from Advent France Biotechnology + BIVF + JDRF T1D Fund |
2020-06-16 |
| eTheRNA–BNP Paribas: investment, 202006 financing round Series B totalling €34m incl new investor BNP Paribas Fortis Equity |
2020-06-16 |
| MedinCell–SEVERAL: investment, 202006 capital increase €15.6m from French + international investors |
2020-06-16 |
| Ona Therapeutics–France (govt): investment, 202006 financing round Series A totalling €30m incl new investor Bpifrance InnoBio 2 |
2020-06-16 |
| Ona Therapeutics–SEVERAL: investment, 202006 financing round Series A €30m |
2020-06-16 |
| Epsilen Bio–Sofinnova: investment, 202006c seed financing €2.3m from Sofinnova Partners through Sofinnova Telethon Fund |
2020-06-15 |
| Corvidia Therapeutics–Novo Group: investment, 202006 acquisition $725m upfront cash + $1.375b milestones cash by Novo Nordisk ANNOUNCED |
2020-06-11 |
| Bioqube Ventures–Belgium (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor Belfius Insurance |
2020-06-10 |
| Bioqube Ventures–Belgium (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor FPIM |
2020-06-10 |
| Bioqube Ventures–EU (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor EIF |
2020-06-10 |
| Bioqube Ventures–Flanders (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor PMV |
2020-06-10 |
| Bioqube Ventures–Genmab: investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl strategic investor Genmab |
2020-06-10 |
| Bioqube Ventures–JnJ: investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl strategic investor JnJ Innovation |
2020-06-10 |
| Bioqube Ventures–Molenwater Groep: investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor Molenwater Groep |
2020-06-10 |
| Bioqube Ventures–SEVERAL: investment, 202006 first closing €60m of Bioqube Factory Fund I investors incl EIF + PMV + FPIM + Genmab + JJDC et al |
2020-06-10 |
| Protera–SEVERAL: investment, 202006 financing round Series A $5.6m led by Sofinnova Partners + incl existing investor SOSV |
2020-06-10 |
| NodThera–SEVERAL: investment, 202006 financing round Series B £44m ($55m) led by Novo Ventures |
2020-06-03 |
| MedinCell–SEVERAL: credit, 202005– state guaranteed PGE loan €10.9m at 0.25% up to 5y from Banque Populaire du Sud + BNP Paribas |
2020-05-27 |
| Tollys–Andrew Lloyd Associates: public relations, 202005 service existent by ALA |
2020-05-26 |
| Tollys–SEVERAL: investment, 202005 financing round Series A €2.3m bringing total raised since founding 2015 to €6.4m |
2020-05-26 |
| Poxel–Trophic Communications: public relations, 202005 service existent IR+ media EU/US by Trophic Communications |
2020-05-25 |
| HotSpot Therapeutics–SEVERAL: investment, 202005 financing round Series B $65m led by SR One |
2020-05-21 |
| HotSpot Therapeutics–Sofinnova: investment, 202005 financing round Series B totalling $65m incl existing + co-investor Sofinnova Partners |
2020-05-21 |
| ElsaLys–Mediolanum: investment, 202005 acquisition of ElsaLys Biotech by Mediolanum Farmaceutici SpA |
2020-05-07 |
| Vaxxel–Transgene: cell line technology, 202005 acquisition €na of DuckCelt-T17 cell line from Transgene incl shareholding for Transgene |
2020-05-04 |
| Vaxxel–Transgene: investment, 202005 investment €na Transgene becomes shareholder as part of acquisition of DuckCelt-T17 cell line by Vaxxel |
2020-05-04 |
| Pfizer–Valneva: Lyme disese vaccine, 202004– collab developm of VLA15 + commerc by Pfizer $130m upfront + $178m milestones + 2-digit tiered royalties |
2020-04-30 |
| PinCell–SEVERAL: investment, 202004 seed financing round €1.65m led by Sofinnova Telethon Fund |
2020-04-30 |
| PinCell–Sofinnova: investment, 202004 seed financing round totalling €1.65m incl lead investor Sofinnova Telethon Fund |
2020-04-30 |
| Genespire–Sofinnova: investment, 202004 Series A financing €16m from Sofinnova Partners |
2020-04-29 |
| Kurma–EU (govt): investment, 202004 final closing of Kurma Biofund III totalling €160m incl investor EIF |
2020-04-29 |
| Kurma–Institut Pasteur: investment, 202004 final closing of Kurma Biofund III totalling €160m incl investor Pasteur Institute |
2020-04-29 |
| Kurma–North Rhine-Westphalia (govt): investment, 202004 final closing of Kurma Biofund III totalling €160m incl investor NRW.BANK |
2020-04-29 |
| Kurma–SEVERAL: investment, 202004 final closing of Kurma Biofund III with €160m |
2020-04-29 |
| MicroPort Scientific–Robocath: cardiovascular devices, 202004– collab strategic agreem to set up joint venture in China for vascular robotics platform |
2020-04-29 |
| Polyplus-transfection–Warburg Pincus: investment, 202004 investment resulting in Warburg Pincus + ArchiMed owning equal shares + voting rights |
2020-04-29 |
| Robocath–MicroPort Scientific: investment, 202004 financing round Series C totalling €40m incl new + lead investor MicroPort Scientific Corp |
2020-04-29 |
| Robocath–SEVERAL: investment, 202004 financing round Series C €40m led by MicroPort Scientific |
2020-04-29 |
| Gustave Roussy–Biognosys: MS-based proteomics, 202004– collab using proteomic profiling in attempt to repurpose tocilizumab for Covid-19 |
2020-04-28 |
| BrainVectis–AskBio: investment, 202004 acquisition €na of BrainVectis by Asklepios BioPharmaceutical |
2020-04-22 |
| EnginZyme–SEVERAL: investment, 202004 financing round Series A €6.4m led by Sofinnova Partners |
2020-04-22 |
| EnginZyme–Sofinnova: investment, 202004 financing round Series A totalling €6.4m incl lead investor Sofinnova Industrial Biotech Fund |
2020-04-22 |
| Valneva–Dynavax: SARS-CoV-2 vaccine, 202004– collab development combining Valneva’s vaccine technology with adjuvant CpG 1018 of Dynavax |
2020-04-22 |
| LNC Therapeutics–Univ Valencia: microbiomic treatment, 202004– license ww excl for patent on Christensenella therapeutics for mood disorders |
2020-04-15 |
| Servier–Gorrissen Federspiel: legal services, 202004 supply service Gorrissen Federspiel legal advisor to Servier w regard to acquisition of Symphogen |
2020-04-03 |
| Servier–Lazard: financial services, 202004 supply service Lazard financial advisor to Servier w regard to acquisition of Symphogen |
2020-04-03 |
| Servier–McDermott Will & Emery: legal services, 202004 supply service MWE legal advisor to Servier w regard to acquisition of Symphogen |
2020-04-03 |
| Symphogen–Perkins Coie: legal services, 202004 supply service Perkins Coie legal advisor to Symphogen w regard to acquisition by Servier |
2020-04-03 |
| Symphogen–Plesner: legal services, 202004 supply service Plesner AP legal advisor to Symphogen w regard to acquisition by Servier |
2020-04-03 |
| Symphogen–Rothschild & Co: financial services, 202004 supply service Rothschild & Co financial advisor to Symphogen w regard to acquisition by Servier |
2020-04-03 |
| Symphogen–Servier: investment, 202004–202006 acquisition 100% €na |
2020-04-03 |
| Lysogene–OrbiMed: investment, 202003 capital increase totalling €7.7m incl €6.6m from new + lead investor OrbiMed Advisors LLC |
2020-03-12 |
| Lysogene–Sarepta: investment, 202003 capital increase totalling €7.7m incl €538k from existing + co-investor Sarepta Therapeutics |
2020-03-12 |
| Lysogene–SEVERAL: investment, 202003 capital increase €7.7m led by OrbiMed Advisors + incl Sarepta Therapeutics at €2.83/share |
2020-03-12 |
| Life Sciences Partners–BMS: investment, 202003 final closing totalling €600m of LSP 6 fund incl investor BMS |
2020-03-10 |
| Life Sciences Partners–EU (govt): investment, 202003 final closing totalling €600m of LSP 6 fund incl investor EIF |
2020-03-10 |
| Life Sciences Partners–Otsuka: investment, 202003 final closing totalling €600m of LSP 6 fund incl investor Otsuka Pharmaceutical |
2020-03-10 |
| Life Sciences Partners–SEVERAL: investment, 202003 final closing €600m of LSP 6 fund with investors incl BMS + Otsuka + EIF |
2020-03-10 |
| Calixar–SEVERAL: investment, 202003 second financing round €2.5m |
2020-03-09 |
| AstraZeneca–Voluntis: digital therapeutics, 202003 collab existent |
2020-03-04 |
| BMS–Voluntis: digital therapeutics, 202003–collab developm of digital therapeutics using Theraxium Oncology platform |
2020-03-03 |
| Ipsen–Genedata: bioinformatics, 202002 supply existent Ipsen is existing customer of Genedata |
2020-02-26 |
| Servier–Genedata: bioinformatics, 202002 supply existent Servier is existing customer of Genedata |
2020-02-26 |
| FinnGen–Sanofi: genomics, 202002 collab existent Sanofi is industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| Scipio Bioscience–BPCE: investment, 202002 financing round Series A totalling €6m incl existing + co-investor Seventure Partners Quadrivium 1 Fund |
2020-02-25 |
| Scipio Bioscience–Financière Arbevel: investment, 202002 financing round Series A totalling €6m incl new + co-investor Financière Arbevel |
2020-02-25 |
| Scipio Bioscience–High-Tech Gründerfonds: investment, 202002 financing round Series A totalling €6m incl existing + co-investor HTGF |
2020-02-25 |
| Scipio Bioscience–Merck (DE): investment, 202002 financing round Series A totalling €6m incl lead investor M Ventures |
2020-02-25 |
| Scipio Bioscience–SEVERAL: investment, 202002 financing round Series A €6m led by M Ventures |
2020-02-25 |
| Scipio Bioscience–Verve Capital Partners: investment, 202002 financing round Series A totalling €6m incl new + co-investor investiere |
2020-02-25 |
| Servier–Cellectis: T-cell immunotherapy, 202002– collab amendment + expansion ww excl license to develop + commercialise UCARTs tageting CD19 |
2020-02-18 |
| Apexbio/Cycloud–Stilla Technologies: digital PCR technology, 202002 distribution existent in China by Apexbio/Cycloud |
2020-02-11 |
| Stilla Technologies–BNP Paribas: investment, 202002 financing round Series B totalling €20m incl existing investor BNP Paribas Développement |
2020-02-11 |
| Stilla Technologies–Eurazeo: investment, 202002 financing round Series B totalling €20m incl existing investor Idinvest Partners |
2020-02-11 |
| Stilla Technologies–Illumina: investment, 202002 financing round Series B totalling €20m incl existing investor Illumina Ventures |
2020-02-11 |
| Stilla Technologies–Kurma: investment, 202002 financing round Series B totalling €20m incl existing investor Kurma Partners |
2020-02-11 |
| Stilla Technologies–LBO France: investment, 202002 financing round Series B totalling €20m incl existing investor LBO France |
2020-02-11 |
![[LSF] Life-Sciences-France.com - The French Life Sciences Web Portal](/images/basics/lsf-life-sciences-france-portal-logo-2019.png){kind=logo}
![Picture [iito] Back into Ad 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-back-into-ad.jpg)
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 120x600px](/banner/iito-20181119-120-600-msc-mass-spec-capital-com.jpg)
